- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00770497
Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.
Effect of Pioglitazone Compared to a Combination Therapy With Ramipril and to a Ramipril Monotherapy on Low Grade Inflammation and Vascular Function in Patients With Increased Cardiovascular Risk and an Activated Inflammation. A Randomized Double-blinded Phase II Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with insulin resistance and an activated inflammation are prone for cardiovascular complications like myocardial infarction or stroke. Pharmacological interventions reducing vascular inflammation are thought to reduce cardiovascular risk in diabetic and in non-diabetic patients.
Intervention with ACE inhibitors like ramipril is an established and widely used treatment for patients with high blood pressure, proven to reduce cardiovascular risk. Treatment of non-diabetic patients with pioglitazone has shown to improve the cardiovascular risk profile in non-diabetic patients beyond its effect on blood glucose levels.
The purpose of this study is to evaluate effects on low grade inflammation and vascular function of pioglitazone in non-diabetic, hypertensive patients with pre treatment with angiotensin converting enzyme inhibitors (that will be replaced by the study medication at time of randomization).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
-
-
Baden-Württemberg
-
Deggingen, Baden-Württemberg, Germany
-
Rottweil, Baden-Württemberg, Germany
-
Spaichingen, Baden-Württemberg, Germany
-
-
Bayern
-
Weilersbach, Bayern, Germany
-
-
Niedersachsen
-
Hannover, Niedersachsen, Germany
-
-
Nordrhein-Westfalen
-
Essen, Nordrhein-Westfalen, Germany
-
Köln, Nordrhein-Westfalen, Germany
-
Werne, Nordrhein-Westfalen, Germany
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Germany
-
Schauenburg, Rheinland-Pfalz, Germany
-
-
Sachsen
-
Dresden, Sachsen, Germany
-
-
Thüringen
-
Blankenhain, Thüringen, Germany
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has arterial hypertension.
- Is on stable treatment with an Angiotensin Converting Enzyme inhibitor at least for 12 weeks.
- Has a high sensitive C-Reactive Protein value greater than 1.0 mg/L and less than 10.0 mg/L.
- Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
Exclusion Criteria:
- Manifests or has newly detected diabetes mellitus type 2 according to World Health Organization criteria.
- Has Type 1 Diabetes.
- Has acute infections.
- Chronic inflammatory diseases which cause elevated CRP-values (e.g. rheumatic diseases, pyelonephritis or osteomyelitis).
- Use of acetyl salicylic acid and/or Non-steroidal Anti-inflammatory Drugs or Cox-2-inhibitors within the last 4 weeks prior to screening visit, use of Rifampicin within the last 12 weeks prior to screening visit.
- Uncontrolled hypertension (repeated blood pressure greater than 180/100 mmHg for at least three times within two weeks); persistent hypotension (systolic less than 90 mmHg) or hemodynamic instability.
- Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.
- History of severe or multiple allergies.
- Treatment with any other investigational drug within 3 months before trial entry.
- Has a progressive, fatal disease.
- History of drug or alcohol abuse within the last 5 years.
- A history of significant cardiovascular (New York Heart Association stage I - IV, hemodynamic relevant aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy), respiratory, gastrointestinal, hepatic (alanine aminotransferase greater than 2.5 times the normal reference range), renal (creatinine greater than 2.0 mg/dL), or hematological disease, history of macular edema.
- State after kidney transplantation, hemodynamic relevant renal artery stenosis (bilateral or unilateral in case of single kidney).
- Blood donation within the last 30 days.
- Serum potassium greater than 5.5 mmol/L.
- History of hyperaldosteronism.
- Treatment with thiazolidinediones within 3 months prior to screening.
- Acute myocardial infarction, open heart surgery or cerebral events (stroke/transient ischemic attack) within 30 days prior to screening visit.
- If statin therapy applicable: Change of medication within the last 12 weeks.
- History of angioneurotic edema (hereditary or idiopathic as consequence of previous Angiotensin Converting Enzyme inhibitor treatment).
- Dialysis or hemofiltration.
- Low Density Lipoprotein apheresis with dextran sulphate.
- Allergic to toxic agents derived from insects.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pioglitazone 15 mg to 30 mg QD
|
Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to: Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks.
Other Names:
|
Active Comparator: Pioglitazone 15 mg to 30 mg QD + Ramipril 2.5 mg to 5 mg QD
|
Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to: Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks.
Other Names:
|
Active Comparator: Ramipril 2.5 mg to 5 mg QD
|
Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to: Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the high-sensitivity C-reactive Protein value.
Time Frame: Week: 12.
|
Week: 12.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in Glucose tolerance as assessed by an oral glucose tolerance test.
Time Frame: Week: 12.
|
Week: 12.
|
Change from Baseline in Insulin sensitivity according to the Homeostatic Model Assessment - Sensitivity score and Insulin Secretion.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Glycosylated Hemoglobin levels.
Time Frame: Week: 12.
|
Week: 12.
|
Change from Baseline in C-Peptide levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Proinsulin intact levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in 24 hours Blood Pressure Profile.
Time Frame: Week: 12.
|
Week: 12.
|
Change from Baseline in high-sensitivity C-reactive Protein levels.
Time Frame: Weeks: 6 and 10.
|
Weeks: 6 and 10.
|
Change from Baseline in Adiponectin levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Monocyte Chemoattractant Protein-1 levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Matrix metalloproteinase-9 levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in P-selectin levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Plasminogen Activator Inhibitor-1 levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Relaxin levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Endothelin 1-21 levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Nitrotyrosine levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Asymmetric Dimethylarginine levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Myeloperoxidase levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in levels of Oxidative Stress as assessed by Per-Ox-Assay.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Total Cholesterol levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Triglycerides levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in High Density Lipoprotein levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Low Density Lipoprotein levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Oxidized Low Density Lipoprotein levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Soluble Intercellular Adhesion Molecule levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Soluble Vascular Cell Adhesion Molecule levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Osteoprotegrin levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in 11-dihydroxy-thromboxan B2 levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Change from Baseline in Placental Growth Factor levels.
Time Frame: Weeks: 6 and 12.
|
Weeks: 6 and 12.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Inflammation
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Angiotensin-Converting Enzyme Inhibitors
- Pioglitazone
- Ramipril
Other Study ID Numbers
- ATS K023
- 2006-004028-35 (EudraCT Number)
- D-PIO-110 (Other Identifier: Takeda ID)
- U1111-1115-9194 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Singapore National Eye CentreCompletedIntraocular Inflammation in ChildrenSingapore
Clinical Trials on Pioglitazone
-
Dong-A ST Co., Ltd.CompletedType 2 DiabetesKorea, Republic of
-
Solvay PharmaceuticalsCompletedType 2 Diabetes MellitusUnited Kingdom
-
Emory UniversityCompletedDiabetic Ketoacidosis | Ketosis Prone Diabetes | Severe HyperglycemiaUnited States
-
University at BuffaloTakeda Pharmaceuticals North America, Inc.Completed
-
National Cancer Institute (NCI)CompletedHead and Neck Cancer | Oral LeukoplakiaUnited States
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceNot yet recruitingANCA Associated Vasculitis | Rapidly Progressive Glomerulonephritis | Crescentic Glomerulonephritis
-
University of Campinas, BrazilRecruitingMyocardial Reperfusion InjuryBrazil
-
West Virginia UniversityRecruitingBreast Cancer | Muscle FatigueUnited States
-
University of Texas Southwestern Medical CenterRecruitingNephrolithiasis, Uric AcidUnited States
-
University of Texas Southwestern Medical CenterNational Institutes of Health (NIH)Completed